GBA Presents: RADIO SAVANT-!

Good Sat AM-- Welcome to MASTER CLASS--

FOUR stock found support at the 21-day line, rebounding to edge up 0.4% to 63.69 for the week. That formed a three-weeks-tight pattern with a 65.89 buy point. Investors also could view the recent pause as a handle to a consolidation going back to April 2022. Still, a few weeks of sideways action that lets the 50-day/10-week line catch up might be ideal. FOUR stock has more than doubled since bottoming in July.

How are we playing this?-- TOAST.!


 
TA-GNRC Generac-- started the day at $114 and finished at $117.70--

Let take a look--

The largest sell stick on GNRC came in on Oct 19-- $147-->$110.

$110 is a capitulation low.<-----

Now we have a mini break out that if it should get above $120 it will get above the recovery high off that $110 low. Meaning the high point GNRC made on that first bounce.

So $120 area is vital get through that w/ vol and there is a large gap to fill up.

Targets- ST $136 and even $170 that would be the Bull case here.

Vol is decreasing down and that is not a good sign when the stk is trending up. What you like to see in a ski slope pattern which is shaped like a big hill is vol to die down as the action on the stk dies... you just peeter out.

But on an upswing you look for green vol bars and I do not see them.-!:caution:

That is a warning sign.

We see a RSI (relative strength) at 62 elevated but not yet overbought.

Accumulation / Distribution very important that line is Negative!<---:caution:

That is a 2nd warning sign.

MACD turned up on Dec 28 in keeping with the stock price. Has now flattened out indicating limited upside.

Last thing we do is lay over Bollinger bands and we see the top looks capped and the bottom leads to $95 area.

Ok: This is a good example of a stock that is going up that could lure folks in and is in fact in a bearish phase called fast stochastic --

The fast stochastic indicator (%K) isa momentum technical indicator that aims to measure the trend in prices and identify trend reversals. The indicator was developed by securities trader and technical analyst George Lane. The indicator is driven by two parameters: the lookback period and the smoothing parameter.


Chart Events
logo-18-18.svg


Bearishpattern detected
generic.svg

Fast Stochastic

So my best guess is GNRC will prove to be a short candidate at $121. ~ si
 
What is a diamond bottom?


A diamond bottom is a bullish, trend reversal, chart pattern.
A diamond bottom is formed by two juxtaposed symmetrical triangles, so forming a diamond.

A diamond bottom has to be preceded by a bearish trend. This pattern marks the exhaustion of the selling current and investor indecision.
Volatility and oscillations increase in the first half of the pattern (i.e. in the symmetric broadening wedge pattern); then decrease in the second half of the pattern (i.e. in the symmetric triangle).

A diamond bottom’s price objective is calculated by plotting the maximum height of the diamond at the exit point.
In general, the exit movement is as fast as the downward movement that preceded it.

Using these parameters $27 is guaranteed on toast<----

-- TOAST- Prices have moved above the 50-day and 200-day moving average lines.

--TOAST- The daily On-Balance-Volume (OBV) line made a low in June and has since improved, buyers of TOST are acting more aggressively than sellers. The Moving Average Convergence Divergence (MACD) oscillator is above the zero line and bullish.

FINAL WORD-BUY TOAST // DON'T BUY GNRC.
 
MAKE IT RAIN-?

Citi opens 'Upside 90-Day Catalyst Watch' on Rain Oncology 07:19 RAIN

This we should look into... what is the catalyst? They must have a product under review...

Research Candidate Of The Day-- RAIN.[/QUOTE]




RAIN->

The team at Rain continues to drive forward our lead late-stage clinical program milademetan, our oral small molecule inhibitor of the p53 MDM2 complex.

We also remind you that we announced a $50 million registered offering last week, concurrent with the release of the early MANTRA-2 data. With this additional capital, Rain’s cash position is even stronger, now providing a cash runway well into 2025

we’re getting closer to the release of results from our pivotal MANTRA trial, the registrational Phase 3 study of mila in patients with specific subtypes of liposarcoma. We completed enrollment with 175 patients in July of this year, and we can now refine our guidance for top-line data to the first quarter of 2023 or next quarter from the prior guidance of the first half of 2023.

OK SO STEP 1 IS YOU READ THROUGH A CC AND FIND WHAT COULD THE " CATALYST " BE

NOW WE KNOW... 90 DAYS FOR THIS INFO.....
 
the MANTRA-4 trial is certainly a priority for Rain, and we expect to start that trial next quarter. The size of the MANTRA-4 target patient population is materially large, and we’re very excited about the science there. Therefore, you’ll notice that after Rain’s initial indication for mila and liposarcoma tumors, which exhibit genetic uniformity, and driven by where the initial data existed at the time of licensing the program, both of our other near-term priority indications represent large market tumor-agnostic basket trials, the MDM2-amplified MANTRA-2 study and the CDKN2A loss MANTRA-4 study.

As a reminder, the benchmark we set out to test was a 30% objective response rate. We are pleased to report that we observed two unconfirmed partial responses and two near partial responses. A patient with pancreatic cancer and a KRAS mutation achieved a partial response at their first scan and is awaiting their second scan, along adenocarcinoma patient with an EGFR exon-19 deletion as well as a KRAS mutation also achieved a PR at their first scan, but sadly died after this initial assessment due to COVID-19.

In addition to these responses, we observed tumor regressions of 29% in a patient with cholangiocarcinoma and an IDH2 mutation and a 27% reduction in a patient with breast cancer harboring a PI3 kinase mutation. All the patients with a PR or near PR, with the exception of the patient disease due to COVID, are continuing on therapy. Of the eight patients still ongoing therapy, the longest patient continues on study for over nine months.
 
For the third quarter of 2022, we reported a net loss of $18 million compared to a net loss of $18.4 million in the third quarter of 2021. Research and development expenses of $14.5 million in the third quarter of 2022 were slightly lower as compared to $15.3 million in the third quarter

NOW HAS $140 MIL CASH<----

with $90.7 million in cash, cash equivalents and short-term investments. As announced last week, we completed a $50 million registered offering of common stock, which increases our pro forma cash balance to over $140 million and provides additional runway well into 2025.
 
WELL IT'S A NICE SAT IN THE COUNTRY AND WE ARE BEYOND EXCITED TO WELCOME A SPECIAL RETURNING GUEST THE AFFABLE, THE SMARTLY DRESSED, THE CONFIDENT MR
MIZUHO-!

Welcome sir a few words on RAIN Oncology please.

Rain Oncology initiated with a Buy at Mizuho 06:36 RAIN Mizuho analyst Graig Suvannavejh initiated coverage of Rain Oncology with a Buy rating and $18 price target. Rain is a precision oncology company advancing milademetan, a novel MDM2 inhibitor with "pipeline-in-a-product potential," the analyst tells investors in a research note. The firm views milademetan as being "meaningfully de-risked," given previously shown Phase 1/2 data in liposarcoma that were "strongly positive."

GBA Upgrade To Buy->RAIN-$10.00

RAIN
Rain Oncology
$10.04

+0.06(+0.60%)

Rain Oncology initiated with a Buy at EF Hutton 01/04 RAIN EF Hutton analyst Tony Butler initiated coverage of Rain Oncology with a Buy rating and $16 price target. Rain is developing milademetan, a small molecule MDM2 inhibitor, as a tumor-agnostic therapy and is in Phase 3 testing against certain subtypes of liposarcomas with top-line data expected in Q1 of this year, Butler tells investors. He sees a "high probability" of the data being positive, which should create momentum for the stock, Butler added.
 
I got an overwhelming response from you all that you want more MASTER CLASSES so I am going to try and give you those.-

If you like these ideas ahead of time so you can plan your week ahead. Please let me know.

It requires a good amount of work on my side. /
 
You must log in or register to reply here.
Back
Top